BPC-157 has a molecular weight of approximately 1,419 Da on the larger end for nasal mucosal absorption which may constrain bioavailability compared to smaller peptides like Semax (which weighs 604 Da and is specifically designed for nasal delivery).8 Who nasal delivery may be relevant for (research context): Neurological or brain-adjacent applications Patients for whom injection is contraindicated Situations requiring rapid onset with non-invasive administration Research protocols studying nose-to-brain peptide pathways What to be realistic about: No peer-reviewed human trials on intranasal BPC-157 exist as of 2026 Nasal absorption of BPC-157 is less predictable than for smaller peptides Dosing standardisation for nasal BPC-157 is not established Consult a licensed provider before considering this route Peptide Delivery Method Comparison Table How to Choose the Right BPC-157 Delivery Method for Your Goal Matching the delivery method to the clinical goal is the single most important decision in BPC-157 therapy
State-Specific Regulations : Some states may have unique regulations that permit phlebotomists to give certain injections after further training
Under normal conditions, it helps maintain genomic integrity
Prescription products require an online consultation with a healthcare provider, who will determine if an individual is eligible for a prescription if medically appropriate in their independent clinical judgement
BPC-157 is a synthetic pentadecapeptide (a peptide made up of 15 amino acids) based on a segment from a natural peptide (BPC) derived from human gastric juice.3 4 Insider Tip: Other names for BPC-157 are body protection compound 157, BPC-15, bepecin, PLD-116, PL-10, and PL-14736. Some also refer to BPC-157 as the Wolverine peptide due to its potential to support healing
